» Articles » PMID: 30383810

Quality by Design (QbD) Based Process Optimisation to Develop Functionalised Particles with Modified Release Properties Using Novel Dry Particle Coating Technique

Overview
Journal PLoS One
Date 2018 Nov 2
PMID 30383810
Citations 5
Authors
Affiliations
Soon will be listed here.
Abstract

Quality by Design (QbD), a current trend employed to develop and optimise various critical pharmaceutical processes, is a systematic approach based on the ethos that quality should be designed into the product itself, not just end tested after manufacture. The present work details a step-wise application of QbD principles to optimise process parameters for production of particles with modified functionalities, using dry particle coating technology. Initial risk assessment identified speed, air pressure, processing time and batch size (independent factors) as having high-to-medium impact on the dry coating process. A design of experiments (DOE) using MODDE software employed a D-optimal design to determine the effect of variations in these factors on identified responses (content uniformity, dissolution rate, particle size and intensity of Fourier transform infrared (FTIR) C = O spectrum). Results showed that batch size had the most significant effect on dissolution rate, particle size and FTIR; with an increase in batch size enhancing dissolution rate, decreasing particle size (depicting absence of coated particles) and increasing the FTIR intensity. While content uniformity was affected by various interaction terms, with speed and batch size having the highest negative effect. Optimal design space for producing functionalised particles with optimal properties required maximum air pressure (40psi), low batch size (6g), speed between 850 to 1500 rpm and processing times between 15 to 60 minutes. The validity and predictive ability of the revised model demonstrated reliability for all experiments. Overall, QbD was demonstrated to provide an expedient and cost effective tool for developing and optimising processes in the pharmaceutical industry.

Citing Articles

The Optimisation of Carrier Selection in Dry Powder Inhaler Formulation and the Role of Surface Energetics.

Abiona O, Wyatt D, Koner J, Mohammed A Biomedicines. 2022; 10(11).

PMID: 36359226 PMC: 9687551. DOI: 10.3390/biomedicines10112707.


An Integrative QbD Approach for the Development and Optimization of Controlled Release Compressed Coated Formulation of Water-Soluble Drugs.

Shah V, Khambhla E, Nivsarkar M, Trivedi R, Patel R AAPS PharmSciTech. 2022; 23(5):120.

PMID: 35460024 DOI: 10.1208/s12249-022-02225-9.


Polymeric Lipid Hybrid Nanoparticles (PLNs) as Emerging Drug Delivery Platform-A Comprehensive Review of Their Properties, Preparation Methods, and Therapeutic Applications.

Sivadasan D, Sultan M, Madkhali O, Almoshari Y, Thangavel N Pharmaceutics. 2021; 13(8).

PMID: 34452251 PMC: 8399620. DOI: 10.3390/pharmaceutics13081291.


Development of orally dissolving films for pediatric-centric administration of anti-epileptic drug topiramate - A design of experiments (DoE) study.

Dahmash E, Iyire A, Alyami H Saudi Pharm J. 2021; 29(7):635-647.

PMID: 34400857 PMC: 8348934. DOI: 10.1016/j.jsps.2021.04.025.


Systemic Design and Evaluation of Ticagrelor-Loaded Nanostructured Lipid Carriers for Enhancing Bioavailability and Antiplatelet Activity.

Son G, Na Y, Wook Huh H, Wang M, Kim M, Han M Pharmaceutics. 2019; 11(5).

PMID: 31071977 PMC: 6572397. DOI: 10.3390/pharmaceutics11050222.

References
1.
Yu L . Pharmaceutical quality by design: product and process development, understanding, and control. Pharm Res. 2008; 25(4):781-91. DOI: 10.1007/s11095-007-9511-1. View

2.
Saharan V, Choudhury P . Dissolution rate enhancement of gliclazide by ordered mixing. Acta Pharm. 2011; 61(3):323-34. DOI: 10.2478/v10007-011-0021-7. View

3.
Ishizaka T, Honda H, Kikuchi Y, Ono K, Katano T, Koishi M . Preparation of drug-diluent hybrid powders by dry processing. J Pharm Pharmacol. 1989; 41(6):361-8. DOI: 10.1111/j.2042-7158.1989.tb06478.x. View

4.
Alhusban F, ElShaer A, Kansara J, Smith A, Grover L, Perrie Y . Investigation of Formulation and Process of Lyophilised Orally Disintegrating Tablet (ODT) Using Novel Amino Acid Combination. Pharmaceutics. 2016; 2(1):1-17. PMC: 3968345. DOI: 10.3390/pharmaceutics2010001. View

5.
Dahmash E, Mohammed A . Functionalised particles using dry powder coating in pharmaceutical drug delivery: promises and challenges. Expert Opin Drug Deliv. 2015; 12(12):1867-79. DOI: 10.1517/17425247.2015.1071351. View